卡培他滨治疗晚期乳腺癌60例临床观察.docVIP

卡培他滨治疗晚期乳腺癌60例临床观察【摘要】 目的 观察卡培他滨(希罗达)对经蒽环类和(或)紫杉类药物治疗后复发或转移性乳腺癌的疗效分析和毒副反应。方法 卡培他滨1250 mg/m2,2次/d,餐后服用,连续服用2周,休息1周,至少2周期后评价疗效。结果 全组60例无CR,PR16例(26.7%),SD32例(53.3%),PD12例(20%),总有效率26.7%,中位无进展生存时间9.8个月。常见副作用为手足综合征,皮肤色素沉着,腹泻,口腔发炎,恶心呕吐,白细胞及血小板减少,大部分为I-II度。结论 应用卡培他滨单药治疗蒽环类和(或)紫杉类治疗后复发或转移性乳腺癌疗效确切,毒副反应轻,应用方便,值得临床推广使用。 【关键词】 卡培他滨;复发/转移性乳腺癌;单药化疗 Capecitabine in the treatment of advanced breast cancer in 60 patients ZHOU Lan, CHEN Yan, YANG Hong-kai.Department of Oncology,Shantou central hospital, Shantou 515031, China 【Abstract】 Objective To observe the efficacy and side effects of Capecitabine in anthrocyclines and/or taxanes pre-treated recurrent or metastatic breast cancer patients.Methods Evaluation of the efficacy was performed at least 2 weeks after the administration of Capecitabine at a dose of 1250 mg/m2 twice daily for 2 weeks with a rest period of 1 week.Results There was no case with CR(complete response)in all group of 60 patients.The PR(partial response)rate, SD(stable disease)rate and PD(progression disease)rate were 26.7%, 53.3% and 20%,respectively, with a overall response rate of 26.7%, and the progression-free median survival was about 9.8 months.The common side effects included hand-foot symdrome, skin pigmentation, diarrhea, xeromatosis, nasea, vomiting, cytopenia and thrombocytopenia, all of which in I-II degree according to the WHO classification of toxicity.Conclusion Capecitabine has an encouraging effect in anthrocycline and/or taxanes pre-treated recurrent or metastatic breast cancer patients with mild side effects and convenient administration, and should be recommended for further clinical application. 【Key words】Capecitabine;Recurrent or metastatic breast cancer; Mono-chemotherapy 作者单位:515031广东省汕头市中心医院肿瘤内科 乳腺癌是妇女中最常见的恶性肿瘤,发病率仍在逐年增加,已为女性恶性肿瘤发病率的首位[1]。虽经手术,化疗,放疗及内分泌等综合治疗,复发转移率仍较高。卡培他滨(希罗达)是一种新型口服氟尿嘧啶类药物,能选择性地作用于肿瘤细胞,具有高效,方便,副作用小等优点。近年来研究表明,卡培他滨对蒽环类和(或)紫杉类药物化疗失败的复发或转移性乳腺癌有较好疗效。2006年1月至2009年8月,我们采用卡培他滨治疗经蒽环类和(或)紫杉类药物化疗失败的晚期乳腺癌60例